MedPath
HSA Product

NOOTROPIL TABLET 1200 mg

Product approved by Health Sciences Authority (SG)

Basic Information

NOOTROPIL TABLET 1200 mg

TABLET, FILM COATED

Regulatory Information

SIN08988P

November 2, 1996

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XN06BX03

Company Information

UCB Pharma S.A.

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Active Ingredients

PIRACETAM

Strength: 1200.00 mg

Detailed Information

Contraindications

**CONTRAINDICATIONS** NOOTROPIL is contraindicated in: - Hypersensitivity to piracetam, other pyrrolidone derivatives or any of the excipients; - Patients with severe renal impairment (renal creatinine clearance of less than 20 ml per minute); - Patients with cerebral haemorrhage; - Patients suffering from Huntington's Chorea.

Indication Information

**INDICATIONS** 1. Studies carried out in the elderly suffering from loss of memory, vertigo, a lack of concentration or of alertness, changes of mood, a deterioration in behaviour and personal negligence, demonstrate an improvement in symptoms. These symptoms can also provide an early warning of the onset of pathological ageing such as Alzheimer's Disease, an Alzheimer type of senile dementia, or the dementia produced by multiple cerebral infarcts. 2. NOOTROPIL is advocated in the treatment of sickle-cell vaso-occlusive crises. 3. Studies have shown some improvement in children with learning difficulties associated with the written word, particularly with textual understanding which cannot be explained by intellectual backwardness, inadequate education or by the family environment. The administration of NOOTROPIL does not replace other measures also well adapted to correct these learning difficulties, such as remedial teaching.

© Copyright 2025. All Rights Reserved by MedPath